Latest news with #CorvusPharmaceuticals
Associated Press
6 days ago
- Business
- Associated Press
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8 Enrollment initiated in extension cohort study exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The data includes 28-day follow up results for all patients in cohort 3 and continues to show earlier and deeper responses in cohort 3 (200 mg twice per day, total daily dose 400 mg) compared to cohorts 1 and 2 (100 mg twice per day and 200 mg once per day, total daily dose 200 mg). Overall, data from cohorts 1-3 of the trial have demonstrated a favorable safety and efficacy profile, including a statistically significant improvement in Eczema Area and Severity Index (EASI) score for the soquelitinib treated patients compared to placebo at day 28 (p=0.036). 'The complete 28-day data from cohort 3 of our Phase 1 trial of soquelitinib in patients with atopic dermatitis is in-line with the data update we provided at the Society for Investigative Dermatology meeting last month,' said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. 'We are encouraged that results from cohort 3 continue to show earlier and deeper responses, along with a reduction in itch, which is an important factor for patients. We look forward to exploring the potential for further improvement in patient results with longer treatment duration that is being studied in our recently initiated extension cohort. Overall, the data to date is supportive of our view that ITK inhibition with soquelitinib has the potential to be a safe, effective and convenient new option for patients with atopic dermatitis and other immune diseases.' Dr. Miller will highlight the new interim data in a presentation at the Jefferies Global Healthcare Conference, which is scheduled for 9:20 am ET / 6:20 am PT on Thursday, June 5, 2025. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days. Soquelitinib Interim Data from the Atopic Dermatitis Phase 1 Clinical Trial As of May 28, 2025, enrollment in cohorts 1, 2 and 3 has been completed for a total of 48 patients and all patients (36 receiving soquelitinib and 12 placebos) had completed the 28-day treatment course. Patients in cohort 3 had more advanced disease with a higher mean baseline EASI score compared to patients in cohorts 1 and 2. At 28 days, the mean reduction in EASI for cohort 3 (n=12) was 64.8%, compared to 54.6% for cohort 1 and 2 combined (n=24) and 34.4% for placebo (n=12). The graphs below (Figures 1 and 2) show the kinetics of response for each of the cohorts and for the combined cohorts 1, 2 and 3. The placebo patients (n=4 per cohort, total n=12) are combined in both graphs. Separation of the curves for patients receiving active drug began at day 15 and increased by day 28 for cohorts 1 and 2. Cohort 3 patients experienced earlier and deeper separation from placebo starting by day 8. EASI scores continue to improve further in treated patients from all cohorts out to day 58. Figure 1: Percent Reduction in Mean EASI Score for Cohorts 1, 2 and 3 . Mean percent change in EASI score over time is shown. Treatment beginning is designated 'Baseline' and days post-baseline are shown. Screening to baseline data is shown and demonstrates relative disease stability. The study blinding remains in effect for the entire 58-day period. Numbers at the top of the graphs indicate numbers of patients evaluated at the various time points. Figure 2: Percent Reduction in Mean EASI Score for Combined Cohorts 1, 2 and 3. The data is displayed below with cohorts combined. Figure 3 below shows the percent of patients that achieved IGA (Investigator Global Assessment) 0 or 1 or EASI 75 at day 28 of treatment. The placebo patients from cohort 1 (n=4), cohort 2 (n=4) and cohort 3 (n=4) are combined, with no placebo patients achieving IGA 0 or 1 or EASI 75. IGA 0 or 1 and EASI 75 have been determined by the U.S. Food and Drug Administration (FDA) to be clinically meaningful and approvable endpoints and have been the endpoints used in clinical trials for other FDA approved treatments for atopic dermatitis. Four additional patients in cohort 3 are now included in the results as compared to the data reported at the Society for Investigative Dermatology (SID) annual meeting in May 2025 (SID data was as of May 6; these four patients had not yet completed the 28-day treatment course). One of the four patients achieved EASI 75 (this patient experienced an 89% reduction in EASI score) and IGA 1 at day 28 of treatment. Figure 3: Percent Patients Achieving Endpoints IGA 0 or 1, EASI 75 at Day 28 of Treatment Patient Reported Reductions in Itch Patients in the trial recorded the intensity of their pruritus, or itch, using the Peak Pruritus Numerical Rating Scale (PP-NRS), which rates the severity of itch on a scale from 0 (no itch) to 10 (the worst itch imaginable). A reduction of ≥4 points from baseline on the PP-NRS is considered to be a clinically meaningful result. In cohort 3, of the patients for whom adequate PP-NRS data was available, 4 of 8 (50%) had a ≥4 point reduction in PP-NRS score from baseline at day 28, with a reduction in itch seen as early as day 8. Of the remaining patients, two had baseline PP-NRS of less than 4 and two had incomplete PP-NRS data. 1 of 10 evaluable placebo patients (10%) experienced a ≥4 point reduction in PP-NRS score at Day 28. Safety Data As of May 28, 2025, no new safety signals have been observed. Soquelitinib was well tolerated, with no dose limiting toxicities (DLTs) and no clinically significant laboratory abnormalities observed in any of the cohorts. No interruption of drug dosing was seen in any of the cohorts. Grade 1/2 adverse events (treatment related and unrelated) were seen in 38.9% of patients receiving soquelitinib and 25% receiving placebo. Only one treatment related adverse event of grade 1 nausea was reported with soquelitinib treatment. Serum Cytokine and Other Biomarker Studies As reported previously, relationships between reductions in certain cytokines with improvement in EASI scores were observed. Reductions in serum cytokine levels were seen for IL-5, IL-9, IL-17, IL-31, IL-33, TSLP and TARC. Differences between responding and non-responding patients were found, while no such relationships were seen in the placebo group, and patients in cohort 3 had greater reductions in cytokines compared to cohorts 1 and 2. Increasing trends were seen in numbers of circulating T regulatory cells, consistent with the presumed mechanism of action of soquelitinib. Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Extension Cohort Corvus also announced that the first patient(s) has/have been enrolled in the recently announced extension cohort of the Phase 1 trial. This cohort is planned to enroll 24 patients randomized 1:1 between active and placebo, with patients in the treatment group receiving the same dose as cohort 3 – 200 mg orally twice per day. The treatment period for this group is 8 weeks, compared to 4 weeks in cohorts 1-3, with the same 30-day follow-up period with no treatment. About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company's lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit or follow the Company on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements related to the potential of the Company's product candidates including soquelitinib and the potential for further improvement in patient results in the extension cohort of the Phase 1 trial of soquelitinib in patients with atopic dermatitis, the design and planned enrollment of the extension cohort, data in support of ITK inhibition with soquelitinib and its potential for patients, and continued advancement of the Company's clinical pipeline. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as 'believe,' 'expect,' 'anticipate,' 'intend,' 'plan,' 'estimate,' 'seek,' 'will,' 'may' or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on May 8, 2025, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company's ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company's estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company's ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; and the Company's ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. +1-650-900-4522 [email protected] MEDIA CONTACT: Sheryl Seapy Real Chemistry +1-949-903-4750 [email protected] Figures accompanying this announcement are available at:
Yahoo
28-05-2025
- Business
- Yahoo
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2025 Jefferies Global Healthcare Conference, which is being held in New York, NY. The presentation will be on Thursday, June 5 from 9:20-9:50 am ET. A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website. About Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company's lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit or follow the Company on LinkedIn. INVESTOR CONTACT:Leiv LeaChief Financial OfficerCorvus Pharmaceuticals, Inc.+1-650-900-4522llea@ MEDIA CONTACT:Sheryl SeapyReal Chemistry+1-949-903-4750sseapy@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Spotlight On Top Penny Stocks For May 2025
The market has been flat in the last week, but it is up 8.0% over the past year, with earnings forecasted to grow by 14% annually. Penny stocks may be a throwback term, but they still offer intriguing opportunities for investors seeking growth at lower price points. By focusing on companies with strong financials and solid fundamentals, these stocks can present valuable prospects for those willing to explore beyond traditional investment avenues. Name Share Price Market Cap Financial Health Rating Safe Bulkers (NYSE:SB) $3.42 $358.57M ★★★★☆☆ IDenta (OTCPK:IDTA) $0.698616 $2.83M ★★★★★★ Tuya (NYSE:TUYA) $2.32 $1.39B ★★★★★★ WM Technology (NasdaqGS:MAPS) $1.12 $188.36M ★★★★★★ Flexible Solutions International (NYSEAM:FSI) $4.45 $56.28M ★★★★★★ Imperial Petroleum (NasdaqCM:IMPP) $2.74 $94.3M ★★★★★★ BAB (OTCPK:BABB) $0.83935 $6.1M ★★★★★★ Dingdong (Cayman) (NYSE:DDL) $2.42 $518.62M ★★★★★★ Lifetime Brands (NasdaqGS:LCUT) $3.23 $72.4M ★★★★★☆ CBAK Energy Technology (NasdaqCM:CBAT) $0.8999 $80.94M ★★★★★☆ Click here to see the full list of 757 stocks from our US Penny Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates targeting proteins essential for immune cell maturation and function in the United States, with a market cap of $301.84 million. Operations: Corvus Pharmaceuticals, Inc. does not report any revenue segments as it is focused on developing product candidates in the clinical stage. Market Cap: $301.84M Corvus Pharmaceuticals, with a market cap of US$301.84 million, is pre-revenue and currently focused on clinical-stage product development. The company recently reported a net income of US$15.19 million for Q1 2025, marking an improvement from the previous year's loss. Corvus's cash runway extends over a year, supported by its debt-free status and sufficient short-term assets covering liabilities. Despite high volatility in share price and ongoing unprofitability, recent positive interim data from its Phase 1 trial for soquelitinib in atopic dermatitis shows potential efficacy and safety benefits, offering promise amidst financial challenges. Jump into the full analysis health report here for a deeper understanding of Corvus Pharmaceuticals. Learn about Corvus Pharmaceuticals' future growth trajectory here. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Definitive Healthcare Corp. offers a SaaS healthcare commercial intelligence platform both in the United States and internationally, with a market cap of approximately $539.99 million. Operations: The company generates revenue of $247.91 million from its Internet Information Providers segment. Market Cap: $539.99M Definitive Healthcare, with a market cap of US$539.99 million, is navigating financial challenges as it remains unprofitable with increasing losses over the past five years. Recent earnings reports show a net loss of US$107.23 million for Q1 2025, while revenue guidance for the year has been slightly raised to US$234-240 million. Despite high volatility and goodwill impairments impacting its financials, the company maintains sufficient cash runway exceeding three years due to positive free cash flow. The management team is relatively new but experienced board members provide stability amid ongoing strategic adjustments in its SaaS healthcare platform operations. Click here and access our complete financial health analysis report to understand the dynamics of Definitive Healthcare. Review our growth performance report to gain insights into Definitive Healthcare's future. Simply Wall St Financial Health Rating: ★★★★★★ Overview: FIGS, Inc., along with its subsidiary FIGS Canada, Inc., is a direct-to-consumer healthcare apparel and lifestyle company operating in the United States and internationally, with a market cap of approximately $799.75 million. Operations: The company's revenue primarily comes from its online retail segment, which generated $561.17 million. Market Cap: $799.75M FIGS, Inc., with a market cap of approximately US$799.75 million, recently reported Q1 2025 sales of US$124.9 million but faced a net loss of US$0.102 million, reflecting challenges in maintaining profitability amidst revenue growth pressures. The company has no debt and its short-term assets significantly exceed liabilities, indicating strong liquidity management. However, profit margins have declined from the previous year and insider selling has been significant recently. Despite these issues, FIGS's earnings are forecast to grow by 40.22% annually, suggesting potential for recovery if strategic adjustments are effectively implemented under its experienced board leadership. Take a closer look at FIGS' potential here in our financial health report. Understand FIGS' earnings outlook by examining our growth report. Dive into all 757 of the US Penny Stocks we have identified here. Curious About Other Options? The latest GPUs need a type of rare earth metal called Terbium and there are only 23 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CRVS NasdaqGS:DH and NYSE:FIGS. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-04-2025
- Business
- Yahoo
Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires?
We recently published a list of . In this article, we are going to take a look at where Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) stands against other best multibagger penny stocks to buy according to billionaires. Penny stocks always seem like bargains for gaining exposure to some of the fastest-growing segments or spectacles, especially when popular stocks cost hundreds or thousands of dollars. Given that some cost as little as $2, they can be tempting for growing money quickly without spending much. While it's possible to achieve significant returns while investing in companies with depressed stock prices, caution is always of utmost importance. Low-priced stocks come with elevated levels of volatility as reduced liquidity makes them speculative, high-risk investments. Over the years, massive penny-stock scams have cheated thousands of investors out of millions of dollars, even as others have generated a fortune out of them. 2024 was one such year where investors betting on penny stocks generated a fortune as the overall stock market remained bullish. Explosive gains came into play as the equity outlook improved on expectations that the US Federal Reserve would cut interest rates. Amid the current correction in the equity market after two years of blockbuster gains, penny stocks are increasingly becoming popular owing to their depressed valuations. President Donald Trump's eldest son, Donald Trump Jr., and Lara Trump have already joined the fray in acquiring significant stakes in a conservative radio network, affirming renewed interest in thinly traded companies. Nevertheless, in the face of rising trade tensions and the lowest consumer confidence seen in almost three years, US markets have faced significant fluctuations. Yet, despite these obstacles, the idea of penny stocks continues to hold relevance as investors hunt for low-cost options with potential for growth. Often linked with smaller or emerging companies, these stocks can present considerable upside when supported by robust financials and sound fundamentals. It is possible to realize impressive returns by investing money into young firms with small market valuations or undervalued stock prices. That is especially the case at a time when President Trump is increasingly pushing for lower interest rates in the US. Like large-cap stocks, penny stocks tend to do well in low-interest rates environments as acquiring capital to accelerate operations and generate shareholder value becomes easier and more affordable for new and emerging companies. For this article, we used a stock screener first to identify stocks priced under $5 that have posted huge gains over the past year (at least 100%). From the obtained dataset, we selected penny stocks with the highest percentage gains in stock performance over the past year (as of April 21). The list is ranked based on the number of billionaires that hold stakes in them, the data for which we sourced from Insider Monkey's proprietary database. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A biotechnology expert discussing the potential of a new anti-CD73 monoclonal antibody in a lecture Pharmaceuticals, Inc. (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company that develops and commercializes immune modulator therapies for a range of cancers, immune disorders, and infectious diseases. Its lead product candidate, soquelitinib, is an oral, small-molecule ITK inhibitor currently in clinical trials for T-cell lymphoma and atopic dermatitis. The stock has rallied 125% over the past year on positive clinical trial results over the past year. In December of last year, it delivered positive interim results from its Phase 1 trial of sokolitinib for treating moderate to severe atopic dermatitis. The results showed a favorable safety and efficacy profile, affirming the drug's potential for chronic skin conditions. Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has already started enrolling patients for the Phase 3 drug trial for relapsed peripheral T-cell lymphoma. While Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) delivered a wider-than-expected loss of $12.1 million in Q4 2024, reflecting increased expenses and strategic investments in the product line. Likewise, Corvus remains in a strong cash position with $52 million in cash and cash equivalent to develop its pipeline. On March 26, Oppenheimer reiterated the Buy rating on the stock and increased the price target to $15, buoyed by the company's pipeline development and financial stability. Overall, CRVS ranks 9th on our list of best multibagger penny stocks to buy according to billionaires. While we acknowledge the potential of CRVS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CRVS but that trades at less than 5 times its earnings check out our report about the . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Upturn
23-04-2025
- Business
- Business Upturn
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025
Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting Company to discuss data on its first quarter 2025 business update conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT on May 8, 2025 SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis will be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting, which is taking place May 7-10, 2025 in San Diego, CA. Presentation details are as follows: Title: Selective Soquelitinib, a selective ITK inhibitor demonstrates activity in atopic dermatitis phase 1 clinical trial by a novel mechanism of action Abstract #: 0437 Presenter: Albert S. Chiou, M.D., MBA, Clinical Associate Professor, Dermatology and Director of Clinical Research in the Department of Dermatology at Stanford University Medical Center Poster Presentation Date and Time: May 8, 2025 from 4:30 – 6:00 pm PT Oral Presentation Date and Time: May 10, 2025 from 9:50 – 10:00 am PT First Quarter 2025 Financial Results Conference Call and Webcast Corvus will present details on the new data from the soquelitinib Phase 1 clinical trial during the Company's first quarter 2025 business update conference call and webcast, which is scheduled for Thursday, May 8, 2025 at 4:30 pm ET / 1:30 pm PT. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 60 days. About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company's lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit or follow the Company on LinkedIn. INVESTOR CONTACT:Leiv LeaChief Financial OfficerCorvus Pharmaceuticals, Inc.+1-650-900-4522 [email protected]
